Importantly, deletion of one allele that encodes aurora kinase A completely abrogated myelofibrosis in a murine MPN model, providing clear genetic evidence that decreasing aurora kinase A activity may provide therapeutic benefit in MF. This evidence concerns the gene AURKA and myeloproliferative disorder.